Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 154

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 154
---
. The principal purposes of our equity and cash incentive plans are to attract, retain and motivate personnel
through the granting of stock-based and cash-based compensation awards, in order to align our interests and the interests of our stockholders
with those of our employees and consultants. In addition, all of our employees are eligible for health insurance, paid and unpaid leaves
including paid parental leave, a retirement plan, life and disability/accident coverage, and parking or commuter assistance and an employee
assistance.

Corporate Information

We were incorporated under
the laws of the state of Delaware on October 2, 2020 under the name Phoenix Biotech Acquisition Corporation. Legacy CERo was incorporated
under the laws of the state of Delaware on September 23, 2016. On February 14, 2024, we consummated a merger with Legacy CERo and subsequently
changed our name to “CERo Therapeutics Holdings, Inc.” Our corporate headquarters are currently located at 210 Haskins Way,
Suite 230, South San Francisco, California 94080, and our telephone number is (650) 407-2376. Our website is www.cero.bio. The
information on our website is not incorporated by reference in this filing or in any other filings we make with the SEC.

Available Information 

Our internet address is www.cero.bio.
Our investor relations website is located at www.cero.bio/investors. We make available free of charge on our investor relations
website under “SEC Filings” our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K,
our directors’ and officers’ Section 16 reports and any amendments to those reports as soon as reasonably practicable after
filing or furnishing such materials to the SEC. They are also available for free on the SEC’s website at www.sec.gov.

We use our investor relations
website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Investors should monitor such website, in addition to following our press releases, SEC filings and public conference calls and webcasts.
Information relating to our corporate governance is also included on our investor relations website. The information in or accessible
through the SEC and our website are not incorporated into, and are not considered part of, this filing.

36

Item 1A. Risk Factors.

In evaluating our business, careful consideration
should be given to the following risk factors, in addition